Clinical trial · no report yet · Phase 2
ABC
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
- NCT02374242 ↗
- Active, not recruiting
- Melanoma Institute Australia
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 134 | |
| Podcasts | 21 | |
| YouTube | 17 | |
| X threads | 15 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Melanoma; Brain Metastases
- Interventions
- Nivolumab; Ipilimumab
- Arms
- Cohort 1 Nivolumab Monotherapy · Active comparator
- Cohort 2 Nivolumab Monotherapy · Active comparator
- Cohort 3 Nivolumab and Ipilimumab · Active comparator
- Enrollment
- 76
- Primary outcomes
- Intracranial response rate
- Sponsor
- Melanoma Institute Australia with Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb
- Start
- Nov 4, 2014
- Primary completion
- Sep 4, 2017
- Results posted
- No
- Registry record
- NCT02374242 · updated Dec 10, 2025
Publications
linked from the registry- Long GV, Atkinson V, Lo SN, Guminski AD, Sandhu SK, Brown MP, Gonzalez M, McArthur GA, Menzies AM. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2025 Mar;26(3):320-330. doi: 10.1016/S1470-2045(24)00735-6. Epub 2025 Feb 17. PubMed 39978375
- Thompson JR, Lai-Kwon J, Morton RL, Guminski AD, Gonzalez M, Atkinson V, Sandhu S, Brown MP, Menzies AM, McArthur GA, Lo SN, Long GV, Bartula I. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy. 2023 Jun;15(8):593-610. doi: 10.2217/imt-2022-0262. Epub 2023 May 2. PubMed 37132182
- Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27. PubMed 29602646